Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1644-1653, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilkins, T. A.
Right arrow Articles by Barron, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilkins, T. A.
Right arrow Articles by Barron, N.

Clinical Chemistry, Vol 31, 1644-1653, Copyright © 1985 by American Association for Clinical Chemistry

Comprehensive study of a thyroxin-analog-based assay for free thyroxin ("Amerlex FT4")

TA Wilkins, JE Midgley and N Barron

The basic theory of thyroxin-analog-based radioimmunoassays for free thyroxin has been extended to evaluate definitively the effects arising from residual binding of the tracer analog to serum proteins. Using experimentally determined binding constants and computer simulation techniques, we studied the effects of thyroxin-analog binding to serum proteins on results of Amerlex FT4 radioimmunoassay, using this improved mathematical model. Results from computer-simulation studies were compared both directly with in vitro experimental results and indirectly with clinical studies. Agreement was good among all three approaches. The relatively weak binding of analog to thyroxin-binding globulin and prealbumin does not significantly perturb Amerlex FT4 assay results. Binding of the analog by albumin has a small but quantifiable effect on assay results, amounting to an intrinsic bias of 0.08 pmol of free thyroxin per liter per gram of albumin per liter for euthyroid serum samples. This bias is unlikely to be important for most clinical laboratory samples, but it may be significant when one is interpreting results for those rare patients with genetic albumin abnormalities such as analbuminemia or familial dysalbuminemic hyperthyroxinemia. Massively increased concentrations of nonesterified fatty acids (e.g., after treatment with heparin) will lead to a spurious increase in free thyroxin in this and most other techniques, including equilibrium dialysis.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. E.M. Midgley and N. D. Christofides
Point: Legitimate and Illegitimate Tests of Free-Analyte Assay Function
Clin. Chem., March 1, 2009; 55(3): 439 - 441.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. E.M. Midgley
Spurious Conclusions on Analog Free Thyroxine Assay Performance
Clin. Chem., September 1, 2007; 53(9): 1714 - 1714.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. E.M. Midgley
Direct and Indirect Free Thyroxine Assay Methods: Theory and Practice
Clin. Chem., August 1, 2001; 47(8): 1353 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. W. Lyon, P. Meinert, G. A. Bruce, V. A. Laxdal, and M. L. Salkie
Influence of Methodology on the Detection and Diagnosis of Congenital Analbuminemia
Clin. Chem., November 1, 1998; 44(11): 2365 - 2367.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.